Close Menu

NEW YORK, June 13 - Celera Genomics will acquire Axys Pharmaceuticals in an effort to support Celera s drug discovery capabilities, the companies said Wednesday. 

Under the stock-for-stock transaction, Axys shareholders will receive $4.65 per share based upon Celera's closing stock price of $41.75 Tuesday. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.